Author

Severine Vermeire

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Severine Vermeire  et al.

LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY
LONG-TERM TREATMENT WITH SUBCUTANEOUS VEDOLIZUMAB IN CROHN’S DISEASE: INTERIM RESULTS FROM THE VISIBLE OPEN-LABEL EXTENSION STUDY

Severine Vermeire  et al.

JAK inhibition and individualised care: comprehensive management in UC (Galapagos) (Complete Session)
JAK inhibition and individualised care: comprehensive management in UC (Galapagos) (Complete Session)

Severine Vermeire  et al.

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: RESULTS FROM THE PHASE 2 AND PHASE 3 CLINICAL PROGRAMMES

Severine Vermeire  et al.

TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL

Severine Vermeire  et al.

DURABILITY OF SYMPTOMATIC AND CLINICAL OUTCOMES IN OZANIMOD-TREATED PATIENTS BY ENDPOINTS OF INCREASING OBJECTIVITY AT TRUE NORTH WEEK 52: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
DURABILITY OF SYMPTOMATIC AND CLINICAL OUTCOMES IN OZANIMOD-TREATED PATIENTS BY ENDPOINTS OF INCREASING OBJECTIVITY AT TRUE NORTH WEEK 52: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Severine Vermeire  et al.

WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS
WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS

Severine Vermeire  et al.

Blazing the trail - From IL-12/23 to IL-23 and beyond (Janssen) (Complete Session)
Blazing the trail - From IL-12/23 to IL-23 and beyond (Janssen) (Complete Session)

Severine Vermeire  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

Severine Vermeire  et al.

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI
IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI

Severine Vermeire  et al.

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Severine Vermeire  et al.

DISEASE ACCEPTANCE, BUT NOT PERCEIVED CONTROL, IS UNIQUELY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE-RELATED DISABILITY
DISEASE ACCEPTANCE, BUT NOT PERCEIVED CONTROL, IS UNIQUELY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE-RELATED DISABILITY

Severine Vermeire  et al.

ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY
ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY

Severine Vermeire  et al.

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

Severine Vermeire  et al.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

Severine Vermeire  et al.

COOKING METHODS ONLY NEGLIGIBLY AFFECT DIETARY FIBER CONTENT AND COMPOSITION
COOKING METHODS ONLY NEGLIGIBLY AFFECT DIETARY FIBER CONTENT AND COMPOSITION

Severine Vermeire  et al.

IMPACT OF OZANIMOD (OZA) ON INTERLEUKIN-17A (IL-17A) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY
IMPACT OF OZANIMOD (OZA) ON INTERLEUKIN-17A (IL-17A) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY

Severine Vermeire  et al.

COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

Severine Vermeire  et al.

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Severine Vermeire  et al.

EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS
EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS

Severine Vermeire  et al.

Item 41 - 60 / 80
1 2
3
4